Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis
Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja‐Wyszomirska, Gideon M. Hirschfield, Olivier Barbier, Piotr Milkiewicz – 12 February 2014 – Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10‐15 mg/kg/day) were included.